Avidity Partners Management
Latest statistics and disclosures from Avidity Partners Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are DNTH, CGON, MDT, BSX, ORKA, and represent 54.04% of Avidity Partners Management's stock portfolio.
- Added to shares of these 10 stocks: DNTH (+$58M), MDT (+$18M), BMY (+$12M), PFE (+$9.3M), MTSR (+$7.4M), ORKA (+$5.9M), JNJ, CI, ABBV, Carlsmed.
- Started 13 new stock positions in KVUE, MDT, ACAD, JNJ, PFE, BMY, IMRX, Carlsmed, CI, ASND. MTSR, WVE, ABBV.
- Reduced shares in these 10 stocks: NTRA (-$21M), , DXCM (-$18M), HNGE (-$17M), EXAS (-$15M), BSX (-$15M), , GMAB (-$12M), RGEN (-$11M), AXSM (-$9.9M).
- Sold out of its positions in ALT, APGE, AXSM, BBIO, CAH, DXCM, DOCS, HNGE, HUM, NTLA.
- Avidity Partners Management was a net seller of stock by $-144M.
- Avidity Partners Management has $439M in assets under management (AUM), dropping by -12.47%.
- Central Index Key (CIK): 0001791827
Tip: Access up to 7 years of quarterly data
Positions held by Avidity Partners Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Avidity Partners Management
Avidity Partners Management holds 43 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Dianthus Therapeutics (DNTH) | 28.7 | $126M | +83% | 3.2M | 39.35 |
|
| Cg Oncology (CGON) | 14.7 | $65M | +6% | 1.6M | 40.28 |
|
| Medtronic SHS (MDT) | 4.1 | $18M | NEW | 191k | 95.24 |
|
| Boston Scientific Corporation (BSX) | 3.7 | $16M | -48% | 164k | 97.63 |
|
| Oruka Therapeutics (ORKA) | 2.9 | $13M | +87% | 660k | 19.23 |
|
| Bristol Myers Squibb (BMY) | 2.6 | $12M | NEW | 258k | 45.10 |
|
| Natera (NTRA) | 2.6 | $11M | -64% | 70k | 160.97 |
|
| Danaher Corporation (DHR) | 2.5 | $11M | -39% | 55k | 198.26 |
|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 2.3 | $10M | -26% | 510k | 20.20 |
|
| Perspective Therapeutics Com New (CATX) | 2.3 | $10M | +61% | 3.0M | 3.43 |
|
| Jade Biosciences Com New (JBIO) | 2.2 | $9.7M | 1.1M | 8.63 |
|
|
| Pfizer (PFE) | 2.1 | $9.3M | NEW | 366k | 25.48 |
|
| Thermo Fisher Scientific (TMO) | 2.1 | $9.2M | -36% | 19k | 485.02 |
|
| Context Therapeutics (CNTX) | 2.0 | $8.7M | +20% | 9.0M | 0.97 |
|
| Genmab A/s Sponsored Ads (GMAB) | 1.7 | $7.6M | -61% | 248k | 30.67 |
|
| Mestera (MTSR) | 1.7 | $7.4M | NEW | 141k | 52.33 |
|
| UnitedHealth (UNH) | 1.4 | $6.1M | -44% | 18k | 345.30 |
|
| Arvinas Ord (ARVN) | 1.4 | $6.0M | +187% | 698k | 8.52 |
|
| AmerisourceBergen (COR) | 1.4 | $5.9M | -42% | 19k | 312.53 |
|
| Encompass Health Corp (EHC) | 1.2 | $5.3M | -43% | 42k | 127.02 |
|
| Johnson & Johnson (JNJ) | 1.1 | $5.0M | NEW | 27k | 185.42 |
|
| Cigna Corp (CI) | 1.1 | $4.8M | NEW | 17k | 288.25 |
|
| Abbvie (ABBV) | 1.0 | $4.6M | NEW | 20k | 231.54 |
|
| McKesson Corporation (MCK) | 1.0 | $4.5M | -57% | 5.8k | 772.54 |
|
| Carlsmed | 1.0 | $4.3M | NEW | 322k | 13.39 |
|
| Kenvue (KVUE) | 1.0 | $4.3M | NEW | 265k | 16.23 |
|
| Immunic (IMUX) | 0.9 | $4.1M | -16% | 4.7M | 0.88 |
|
| Arcutis Biotherapeutics (ARQT) | 0.9 | $4.0M | -20% | 214k | 18.85 |
|
| EXACT Sciences Corporation (EXAS) | 0.9 | $4.0M | -79% | 74k | 54.71 |
|
| Phathom Pharmaceuticals (PHAT) | 0.8 | $3.6M | -71% | 306k | 11.77 |
|
| Repligen Corporation (RGEN) | 0.7 | $3.1M | -78% | 23k | 133.67 |
|
| ACADIA Pharmaceuticals (ACAD) | 0.7 | $3.1M | NEW | 144k | 21.34 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.7 | $2.9M | NEW | 15k | 198.81 |
|
| Enliven Therapeutics (ELVN) | 0.7 | $2.9M | +1141% | 140k | 20.47 |
|
| Beam Therapeutics (BEAM) | 0.6 | $2.7M | -72% | 112k | 24.27 |
|
| Scynexis Com New (SCYX) | 0.6 | $2.6M | +172% | 3.4M | 0.77 |
|
| Healthequity (HQY) | 0.5 | $2.4M | -72% | 25k | 94.77 |
|
| Wave Life Sciences SHS (WVE) | 0.5 | $2.2M | NEW | 298k | 7.32 |
|
| Xenon Pharmaceuticals (XENE) | 0.5 | $2.1M | -50% | 53k | 40.15 |
|
| Akero Therapeutics (AKRO) | 0.4 | $1.9M | -69% | 41k | 47.48 |
|
| Insmed Com Par $.01 (INSM) | 0.4 | $1.7M | -80% | 12k | 144.01 |
|
| Karyopharm Therapeutics Com New (KPTI) | 0.2 | $880k | 135k | 6.54 |
|
|
| Immuneering Corp Class A Com (IMRX) | 0.1 | $636k | NEW | 91k | 7.00 |
|
Past Filings by Avidity Partners Management
SEC 13F filings are viewable for Avidity Partners Management going back to 2019
- Avidity Partners Management 2025 Q3 filed Nov. 14, 2025
- Avidity Partners Management 2025 Q2 filed Aug. 14, 2025
- Avidity Partners Management 2025 Q1 filed May 15, 2025
- Avidity Partners Management 2024 Q4 filed Feb. 14, 2025
- Avidity Partners Management 2024 Q3 filed Nov. 14, 2024
- Avidity Partners Management 2024 Q2 filed Aug. 14, 2024
- Avidity Partners Management 2024 Q1 filed May 15, 2024
- Avidity Partners Management 2023 Q4 filed Feb. 14, 2024
- Avidity Partners Management 2023 Q3 filed Nov. 14, 2023
- Avidity Partners Management 2023 Q2 filed Aug. 14, 2023
- Avidity Partners Management 2023 Q1 filed May 15, 2023
- Avidity Partners Management 2022 Q4 filed Feb. 14, 2023
- Avidity Partners Management 2022 Q3 filed Nov. 14, 2022
- Avidity Partners Management 2022 Q2 filed Aug. 15, 2022
- Avidity Partners Management 2022 Q1 filed May 16, 2022
- Avidity Partners Management 2021 Q4 filed Feb. 14, 2022